Patents by Inventor Dennis S. Yamashita
Dennis S. Yamashita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11951094Abstract: The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.Type: GrantFiled: June 15, 2022Date of Patent: April 9, 2024Assignee: Axial Therapeutics, Inc.Inventors: Christopher J. Oalmann, Dennis S. Yamashita, Patrick J. Stern
-
Publication number: 20230131899Abstract: The present disclosure provides compounds useful for the prevention of amyloid formation and the treatment of amyloid related disorders, including synucleopathies such as Parkinson's Disease.Type: ApplicationFiled: January 8, 2021Publication date: April 27, 2023Applicant: Axial Therapeutics, Inc.Inventors: Anthony Stewart Campbell, Christopher J. Oalmann, Dennis S. Yamashita
-
Publication number: 20230051773Abstract: The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.Type: ApplicationFiled: June 15, 2022Publication date: February 16, 2023Applicant: Axial Therapeutics, Inc.Inventors: Christopher J. Oalmann, Dennis S. Yamashita, Patrick J. Stern
-
Publication number: 20160287561Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.Type: ApplicationFiled: April 13, 2016Publication date: October 6, 2016Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding, Simon Peace, Dennis S. Yamashita, Kenneth C. McNulty
-
Publication number: 20150152092Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.Type: ApplicationFiled: December 8, 2014Publication date: June 4, 2015Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding, Simon Peace, Dennis S. Yamashita, Kenneth C. McNulty
-
Patent number: 8946278Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.Type: GrantFiled: February 22, 2013Date of Patent: February 3, 2015Assignee: GlaxoSmithKline LLCInventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding, Dennis S. Yamashita, Kenneth C. McNulty
-
Publication number: 20130231378Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.Type: ApplicationFiled: February 22, 2013Publication date: September 5, 2013Applicant: GlaxoSmithKline LLCInventors: Mark A. SEEFELD, Meagan B. Rouse, Dirk A. Heerding, Dennis S. Yamashita, Kenneth C. McMulty
-
Publication number: 20110129455Abstract: Invented are novel pyrrole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.Type: ApplicationFiled: June 24, 2009Publication date: June 2, 2011Inventors: Hong Lin, Meagan B. Rouse, Mark A. Seefeld, Dennis S. Yamashita, Ren Xie
-
Publication number: 20100267759Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.Type: ApplicationFiled: February 7, 2008Publication date: October 21, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding, Simon Peace, Dennis S. Yamashita, Kenneth C. McNulty
-
Patent number: 7563784Abstract: The present invention provides C1-6alkyl-4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease; and parasitic diseases, including malaria, by administering to a patient in need thereof one or more compounds of the present invention.Type: GrantFiled: April 25, 2006Date of Patent: July 21, 2009Assignee: SmithKline Beecham CorporationInventors: Maxwell D. Cummings, Robert W. Marquis, Jr., Yu Ru, Scott K. Thompson, Daniel F. Veber, Dennis S. Yamashita
-
Publication number: 20090137557Abstract: Novel calcilytic compounds, pharmaceutical compositions, methods of synthesis and methods of using them are provided.Type: ApplicationFiled: November 21, 2006Publication date: May 28, 2009Inventors: Thomas Wen Fu Ku, Hong Lin, Juan I. Luengo, Robert W. Marquis Jr., Joshi M. Ramanjulu, Robert Trout, Dennis S. Yamashita
-
Publication number: 20080255143Abstract: Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.Type: ApplicationFiled: July 28, 2004Publication date: October 16, 2008Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Dirk A. Heerding, Tammy J. Clark, David Harold Drewry, Jack Dale Leber, Igor Safonov, Dennis S. Yamashita
-
Patent number: 7109233Abstract: This invention relates in general to certain substituted substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamides of formula I as defined herein which are protease inhibitors.Type: GrantFiled: May 21, 2003Date of Patent: September 19, 2006Assignee: SMithKline Beecham CorporationInventors: Jae U. Jeong, Dennis S. Yamashita
-
Patent number: 7071184Abstract: The present invention provides C1-6alkyl-4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease; and parasitic diseases, including malaria, by administering to a patient in need thereof one or more compounds of the present invention.Type: GrantFiled: March 7, 2001Date of Patent: July 4, 2006Assignee: SmithKline Beecham CorporationInventors: Maxwell D. Cummings, Robert W. Marquis, Jr., Daniel F. Veber, Dennis S. Yamashita
-
Publication number: 20040229863Abstract: The present invention provides methods which use 4-amino-azepan-3-one protease inhibitors of cathepsin S in the treatment of diseases in which cathepsin S is implicated, especially treatment or prevention of autoimmune disease; treatment or prevention of a disease state caused by the formation of atherosclerotic lesions and complications arising therefrom; and diseases requiring inhibition, for therapy, of a class II MHC-restricted immune response, inhibition of an asthmatic response, inhibition of an allergic response, inhibition of immune response against a transplanted organ or tissue, or inhibition of elastase activity in atheroma, and novel compounds for use therewith.Type: ApplicationFiled: March 10, 2004Publication date: November 18, 2004Applicant: SmithKline Beecham CorporationInventors: Maxwell D. Cummings, Robert W. Marquis, Yu Ru, Scott K. Thompson, Daniel F. Veber, Dennis S. Yamashita
-
Publication number: 20040157828Abstract: The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.Type: ApplicationFiled: November 17, 2003Publication date: August 12, 2004Inventors: Ren Xie, Dennis S Yamashita
-
Publication number: 20040044201Abstract: The present invention provides C1-6alkyl-4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease; and parasitic diseases, including malaria, by administering to a patient in need thereof one or more compounds of the present invention.Type: ApplicationFiled: September 20, 2002Publication date: March 4, 2004Inventors: Maxwell D. Cummings, Robert W. Marquis Jr., Yu Ru, Scott K. Thompson, Daniel F. Veber, Dennis S. Yamashita
-
Publication number: 20040038965Abstract: The present invention provides C3-C6 1-amino-1-acyl cycloalkane-substituted 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.Type: ApplicationFiled: May 22, 2003Publication date: February 26, 2004Inventors: Robert W. Marquis, Jr., Daniel F. Veber, Dennis S. Yamashita
-
Publication number: 20040034013Abstract: The present invention provides methods which use 4-amino-azepan-3-one protease inhibitors of cathepsin L in the treatment of diseases in which cathepsin L is implicated, especially treatment or prevention of rheumatoid arthritis; treatment or prevention of cancer metastasis; treatment or prevention of diseases requiring inhibition of tissue destruction by macrophage, particularly lung macrophage, such as asthma, chronic obstructive pulmonary disease (COPD), and emphysema; treatment or prevention of diseases requiring, for therapy, inhibition of positive selection of CD4+ T-cells by cortical thymic epithelial cells.Type: ApplicationFiled: October 17, 2002Publication date: February 19, 2004Inventors: Maxwell D Cummings, Robert W Marquis, Yu Ru, Scott K Thompson, Daniel F Veber, Dennis S Yamashita
-
Publication number: 20030114437Abstract: The present invention provides methods which use 4-amino-azepan-3-one protease inhibitors of cathepsin S in the treatment of diseases in which cathepsin S is implicated, especially treatment or prevention of autoimmune disease; treatment or prevention of a disease state caused by the formation of atherosclerotic lesions and complications arising therefrom; and diseases requiring inhibition, for therapy, of a class II MHC-restricted immune response, inhibition of an asthmatic response, inhibition of an allergic response, inhibition of immune response against a transplanted organ or tissue, or inhibition of elastase activity in atheroma, and novel compounds for use therewith.Type: ApplicationFiled: October 17, 2002Publication date: June 19, 2003Inventors: Maxwell D. Cummings, Robert W. Marquis Jr, Yu Ru, Scott K. Thompson, Daniel F. Veber, Dennis S. Yamashita